H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on Arcellx Inc (ACLX – Research Report) today and set a price target of $115.00.
Emily Bodnar’s rating is based on several compelling factors. Arcellx Inc’s anito-cel therapy has demonstrated promising clinical results in the treatment of relapsed or refractory multiple myeloma, with a high overall response rate and a significant complete response rate. The absence of delayed neurotoxicities in a substantial patient cohort further enhances its safety profile, distinguishing it from competitor therapies.
Additionally, the strategic partnership with Kite Pharma provides Arcellx with a strong manufacturing and commercialization advantage, ensuring efficient product turnaround times. The ongoing expansion of the ARC-SparX program and the initiation of a Phase 1 study for myasthenia gravis highlight the company’s commitment to broadening its therapeutic applications. These factors collectively support the Buy rating, positioning anito-cel as a potentially best-in-class BCMA CAR-T therapy with a commercial launch anticipated in 2026.
Bodnar covers the Healthcare sector, focusing on stocks such as AnaptysBio, Agenus, and NovoCure. According to TipRanks, Bodnar has an average return of -4.0% and a 26.69% success rate on recommended stocks.
In another report released today, Barclays also maintained a Buy rating on the stock with a $115.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com